PremiumRatingsStrategic Advancements and Regulatory Progress Drive Buy Rating for Applied Therapeutics Applied Therapeutics Reports Q1 2025 Financial Results Applied Therapeutics reports Q1 EPS (15c), consensus (18c) PremiumThe FlyApplied Therapeutics files Form 12b-25 with SEC Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer APLT Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumThe FlyMorning Movers: Despegar surges following deal to be acquired by Prosus William Blair downgrades Applied Therapeutics on revenue uncertainty Applied Therapeutics downgraded to Market Perform from Outperform at William Blair 
